David A Proia
Overview
Explore the profile of David A Proia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
1348
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sun D, Nikonova A, Zhang P, Deneka A, Fitzgerald M, Michael R, et al.
Mol Cancer Ther
. 2021 May;
20(8):1367-1377.
PMID: 34045230
Targeted, catalytic degradation of oncoproteins using heterobifunctional small molecules is an attractive modality, particularly for hematologic malignancies, which are often initiated by aberrant transcription factors and are challenging to drug...
2.
Vieux E, Agafonov R, Emerson L, Isasa M, Deibler R, Simard J, et al.
SLAS Discov
. 2021 Mar;
26(4):547-559.
PMID: 33780296
Recent advances in targeted protein degradation have enabled chemical hijacking of the ubiquitin-proteasome system to treat disease. The catalytic rate of cereblon (CRBN)-dependent bifunctional degradation activating compounds (BiDAC), which recruit...
3.
Jansson K, Tucker J, Stahl L, Simmons J, Fuller C, Beshiri M, et al.
Sci Rep
. 2018 Nov;
8(1):17239.
PMID: 30467317
The development of new treatments for castrate resistant prostate cancer (CRPC) must address such challenges as intrinsic tumor heterogeneity and phenotypic plasticity. Combined PTEN/TP53 alterations represent a major genotype of...
4.
London C, Acquaviva J, Smith D, Sequeira M, Ogawa L, Gardner H, et al.
Clin Cancer Res
. 2018 Sep;
24(24):6396-6407.
PMID: 30171047
Purpose: STA-1474, prodrug of the heat shock protein 90 inhibitor (HSP90i) ganetespib, previously demonstrated activity in canine preclinical models of cancer; interestingly, prolonged infusions were associated with improved biologic activity....
5.
Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD)
Nikonova A, Deneka A, Kiseleva A, Korobeynikov V, Gaponova A, Serebriiskii I, et al.
FASEB J
. 2018 Feb;
32(5):2735-2746.
PMID: 29401581
Autosomal-dominant polycystic kidney disease (ADPKD) is associated with progressive formation of renal cysts, kidney enlargement, hypertension, and typically end-stage renal disease. In ADPKD, inherited mutations disrupt function of the polycystins...
6.
Bobrov E, Skobeleva N, Restifo D, Beglyarova N, Cai K, Handorf E, et al.
Oncotarget
. 2016 Oct;
8(3):4399-4409.
PMID: 27779106
The lack of effective treatment modalities is a major problem in pancreatic cancer (PCa), a devastating malignancy that is nearly universally driven by the "undruggable" KRAS and TP53 cancer genes....
7.
Shatzer A, Ali M, Chavez M, Dowdell K, Lee M, Tomita Y, et al.
Leuk Lymphoma
. 2016 Oct;
58(4):923-931.
PMID: 27686857
HSP90 inhibitors have been shown to kill Epstein-Barr virus (EBV)-infected cells by reducing the level of EBV EBNA-1 and/or LMP1. We treated virus-infected cells with ganetespib, an HSP90 inhibitor currently...
8.
Heske C, Mendoza A, Edessa L, Baumgart J, Lee S, Trepel J, et al.
Oncotarget
. 2016 Sep;
7(40):65540-65552.
PMID: 27608846
Long-term survival in patients with metastatic, relapsed, or recurrent Ewing sarcoma and rhabdomyosarcoma is dismal. Irinotecan, a topoisomerase 1 inhibitor, has activity in these sarcomas, but due to poor bioavailability...
9.
Beck T, Korobeynikov V, Kudinov A, Georgopoulos R, Solanki N, Andrews-Hoke M, et al.
Cell Rep
. 2016 Jul;
16(3):657-71.
PMID: 27396341
Anti-Müllerian hormone (AMH) and its type II receptor AMHR2, both previously thought to primarily function in gonadal tissue, were unexpectedly identified as potent regulators of transforming growth factor (TGF-β)/bone morphogenetic...
10.
Wang Y, Liu H, Diao L, Potter A, Zhang J, Qiao Y, et al.
Clin Cancer Res
. 2016 Jun;
22(23):5876-5886.
PMID: 27354472
Purpose: HSP90 inhibition is well known to sensitize cancer cells to radiation. However, it is currently unknown whether additional radiosensitization could occur in the more clinically relevant setting of chemoradiation...